ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08945
-0,01%
Bitcoin
66.832,32
-0,37%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Syndax Pharmaceuticals Inc (SNDX)

  7. Syndax Pharmaceuticals Inc (SNDX) News

SNDX

Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SNDX
DatumZeitQuelleÜberschriftSymbolFirma
16/05/202422h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
16/05/202422h03Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
15/05/202422h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
15/05/202422h05PR Newswire (US)Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of DirectorsNASDAQ:SNDXSyndax Pharmaceuticals Inc
09/05/202413h00PR Newswire (US)Syndax Announces Participation at the Bank of America Securities 2024 Health Care ConferenceNASDAQ:SNDXSyndax Pharmaceuticals Inc
08/05/202413h06PR Newswire (US)Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business UpdateNASDAQ:SNDXSyndax Pharmaceuticals Inc
08/05/202413h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNDXSyndax Pharmaceuticals Inc
08/05/202413h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
03/05/202422h05PR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
01/05/202413h00PR Newswire (US)Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
10/04/202422h05PR Newswire (US)Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology ForumNASDAQ:SNDXSyndax Pharmaceuticals Inc
08/04/202413h00PR Newswire (US)Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary SessionNASDAQ:SNDXSyndax Pharmaceuticals Inc
05/04/202422h05PR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
28/03/202412h00PR Newswire (US)Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid LeukemiaNASDAQ:SNDXSyndax Pharmaceuticals Inc
26/03/202421h05PR Newswire (US)Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute LeukemiaNASDAQ:SNDXSyndax Pharmaceuticals Inc
18/03/202412h00PR Newswire (US)Syndax Announces Appointment of Steven Closter as Chief Commercial OfficerNASDAQ:SNDXSyndax Pharmaceuticals Inc
01/03/202422h05PR Newswire (US)Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:SNDXSyndax Pharmaceuticals Inc
27/02/202423h28Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:SNDXSyndax Pharmaceuticals Inc
27/02/202423h21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SNDXSyndax Pharmaceuticals Inc
27/02/202422h05PR Newswire (US)Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business UpdateNASDAQ:SNDXSyndax Pharmaceuticals Inc
27/02/202422h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNDXSyndax Pharmaceuticals Inc
26/02/202413h00PR Newswire (US)Syndax Announces Participation at Two Upcoming Investor ConferencesNASDAQ:SNDXSyndax Pharmaceuticals Inc
20/02/202422h05PR Newswire (US)Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024NASDAQ:SNDXSyndax Pharmaceuticals Inc
14/02/202418h50Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SNDXSyndax Pharmaceuticals Inc
14/02/202413h01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNDXSyndax Pharmaceuticals Inc
14/02/202403h44Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNDXSyndax Pharmaceuticals Inc
09/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
09/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
09/02/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
09/02/202422h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNDXSyndax Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SNDX

Kürzlich von Ihnen besucht

LSE
58OF
Sg Issuer 23
AMEX
SWAR
Direxion Daily Software ...
NASDAQ
JFBC
Jeffersonville Bancorp
BIT
F15474
Vontobel Financial Produ...
LSE
FF12
Citi Fun 25
LSE
KDNC
Cadence Minerals
LSE
MSQA
EU
3049T
3049T
LSE
0RN3
Takeda Pharmaceutical
BIT
Q00330
Leonteq Securities
NASDAQ
ALOG
Analogic
BOV
HBOR3R
HELBOR ON
UNSW3
STIXETH
Stickman Saga
LSE
0W7P
Deka Deutsche Boerse Eur...
LSE
JUDS
Jpm Act Us Eq D
NASDAQ
AINN
Applied Innovation
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten